Arcturus Therapeutics Announces Phase II Dosing Timeline for ARCT-2601 and LUNAR 2.0 Platform Advancements
Arcturus Therapeutics (ARCT) has announced plans to begin Phase II dosing of its ARCT-2601 program next quarter. The company expects to release top-line data from this clinical stage in the second half of 2027. This development follows significant technical progress with their LUNAR 2.0 delivery platform, which reportedly demonstrated a 38-fold increase in potency. During its Q3 2026 management update, the company highlighted continued advancement across its key clinical programs and an expansion of its mRNA pipeline. The introduction of the next-generation LUNAR 2.0 platform represents a strategic effort to enhance delivery efficiency for their therapeutic candidates.
Tickers: $ARCT
Topics: clinical programs drug delivery platform mRNA technology